Wang Xuehan, Regenold Maximilian, Dunne Michael, Bannigan Pauric, Allen Christine
Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, M5S 3M2, Canada.
Data Brief. 2023 Sep 9;50:109545. doi: 10.1016/j.dib.2023.109545. eCollection 2023 Oct.
Thermosensitive liposomes in combination with localized mild hyperthermia can improve the delivery of drug to solid tumor sites. For this reason, thermosensitive liposome formulations of a range of chemotherapy drugs have been designed. Our group previously developed and characterized a thermosensitive liposome formulation of the heat shock protein 90 inhibitor alvespimycin as a companion therapeutic to a thermosensitive liposome formulation equivalent in composition to ThermoDox (i.e., ThermoDXR), with the goal of increasing the therapeutic index of doxorubicin as the combination was revealed to be highly synergistic in a panel of human breast cancer cell lines including MDA-MB-231 (Dunne et al., 2019). The data presented here further describes the effect of the doxorubicin (DXR) and alvespimycin (ALV) combination and . Specifically, the combination effect in mouse breast cancer 4T1 cells and the efficacy of this heat-activated chemotherapy combination in both immunocompromised (MDA-MB-231 tumor bearing female SCID mice) and immunocompetent (4T1 tumor bearing female BALB/c mice) models of breast cancer.
热敏脂质体与局部轻度热疗相结合可改善药物向实体瘤部位的递送。因此，已经设计了一系列化疗药物的热敏脂质体制剂。我们小组之前开发并表征了热休克蛋白90抑制剂阿维司比星的热敏脂质体制剂，作为与成分等同于ThermoDox（即ThermoDXR）的热敏脂质体制剂的联合治疗药物，目的是提高阿霉素的治疗指数，因为该组合在包括MDA-MB-231在内的一组人乳腺癌细胞系中显示出高度协同作用（邓恩等人，2019年）。此处呈现的数据进一步描述了阿霉素（DXR）和阿维司比星（ALV）组合的效果。具体而言，是在小鼠乳腺癌4T1细胞中的联合效应以及这种热激活化疗组合在免疫受损（携带MDA-MB-231肿瘤的雌性SCID小鼠）和免疫健全（携带4T1肿瘤的雌性BALB/c小鼠）乳腺癌模型中的疗效。
